Abeona Therapeutics Inc

Abeona Therapeutics reported second-quarter results showing ZEVASKYN revenue of $11.4 million, a 31% increase from the first quarter, and secured a new technology add-on payment from the Centers for Medicare and Medicaid Services effective October 1, 2026. The company has treated 12 patients since launch, including five in the second quarter and three more in the third quarter to date, with its treatment center network expanding to seven activated sites. However, the net loss widened to $20.2 million, or $0.35 per share, from $17.1 million, or $0.30 per share, and one low-yield batch in the second quarter plus one out-of-specification batch in the third quarter generated no revenue despite patients being treated. Abeona also announced it will stop reporting leading indicators like scheduled biopsies and instead report only patients treated and revenue recognized each quarter.

The global regenerative medicine market is projected to reach approximately USD 162 billion by 2034, growing at a compound annual growth rate of around 16% from a 2025 size of about USD 41 billion, according to a report by DelveInsight. North America held the largest share at roughly 42% in 2025, driven by advanced healthcare infrastructure and strong R&D investment, while the Asia-Pacific region is expected to be one of the fastest-growing markets. Key companies in the space include Novartis AG, Gilead Sciences, Bristol-Myers Squibb, Johnson & Johnson, and Krystal Biotech, among others. Recent developments include the European Commission's approval of Krystal Biotech's gene therapy Vyjuvek in April 2025 and the U.S. FDA's approval of Abeona Therapeutics' Zevaskyn, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa. Growth is fueled by advances in stem cell and gene therapies, rising chronic disease prevalence, and supportive regulatory pathways.